Effect of Niacin/Laropiprant on Postprandial Lipoprotein and Glucose Metabolism in Patients With Severe Dyslipoproteinemia.
Phase of Trial: Phase IV
Latest Information Update: 30 Mar 2013
At a glance
- Drugs Niacin/laropiprant (Primary)
- Indications Dyslipidaemias
- Focus Biomarker; Pharmacodynamics
- 12 Feb 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 07 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 22 Jun 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.